(Q39257661)

10 September 2017

title

Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer (English)

1 reference

10 September 2017

main subject

phase II clinical trial

0 references

author

Vasilis Karavasilis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Tamas Hickish

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

L Rhoda Molife

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Aurelius Omlin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Rob J Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

David Bloomfield

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Graeme Lumsden

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter C Fong

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

David Olmos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Joe M O'Sullivan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ian Pedley

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter Jenkins

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Emilda Thompson

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Nikhil Oommen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Duncan Wheatley

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Catherine Heath

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Graham Temple

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Katy Pelling

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Johann S de Bono

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

1 February 2014

1 reference

10 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

219-231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

Prostate cancer incidence and mortality trends in 37 European countries: an overview.

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Alpha emitter radium-223 and survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Nonreceptor tyrosine kinases in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

The role of Src in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

A modification of Simon's optimal design for phase II trials when the criterion is median sample size

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

FGF receptor inhibitors: role in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

Development of therapeutic combinations targeting major cancer signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.250

21 January 2018

Identifiers

DOI

10.2217/FON.13.250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24490608%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference